What is splenic marginal zone lymphoma?

Splenic marginal zone lymphoma (SMZL) is a rare type of blood cancer.

It develops when blood cells called lymphocytes become abnormal. These blood cells normally help fight infection.

The abnormal lymphocytes build up in the spleen. The spleen is an organ in the tummy (abdomen). It helps fight and filter out disease and germs. It also helps clean the blood by removing old blood cells. The spleen is part of the lymphatic system.

The abnormal lymphocytes can also build up in other areas, including:

  • bone marrow – this is the spongy material in the middle of bones where blood cells are made
  • the blood.

Other types of marginal zone lymphoma

SMZL is 1 of 3 types of marginal zone lymphoma. The other 2 types are:

If you are still having tests or waiting for a clear diagnosis, your doctor may talk to you about all 3 types.

Booklets and resources

Symptoms of SMZL

SMZL usually does not cause many obvious symptoms to start with.

The spleen may become bigger if lymphoma cells build up there. This can cause discomfort or pain in the upper part of the tummy and a reduced appetite. An enlarged spleen is called splenomegaly.

Some people with SMZL have a low number of blood cells. This may cause the following symptoms:

  • tiredness
  • shortness of breath
  • bruising or bleeding easily
  • repeat infections.

A low number of blood cells is usually caused by an enlarged spleen removing too many blood cells. But it can also happen if the lymphoma affects the bone marrow and stops it making normal blood cells properly.

B symptoms

SMZL may also cause the following symptoms:

  • drenching night sweats
  • unexplained high temperatures
  • unexplained weight loss.

These are called B symptoms. Along with staging and grading (below), B symptoms can help your cancer team understand:

  • how the lymphoma might develop
  • which treatments might help.

Worried about symptoms?

A change in how you feel or how your body works can be caused by conditions other than SMZL. But always ask your GP to check any ongoing, new or unexplained symptoms.

We are also here if you need someone to talk to. You can:

Related pages

Causes of SMZL

The causes of SMZL are mostly unknown. It is sometimes linked to long term infection with the hepatitis C virus (HCV). But it is important to remember that most people with HCV will not develop lymphoma.

SMZL can affect people of all ages. But it is most common in people over 70.

Like other cancers, SMZL is not infectious. You cannot spread it to other people.

We have more information about the causes and risk factors for non-Hodgkin lymphoma.

Diagnosis of SMZL

Many people will have no symptoms to start with. The lymphoma is sometimes discovered during checks for other conditions – for example, during an examination of the tummy or a blood test for something else.

The main tests to diagnose SMZL are:

Rarely, SMZL is diagnosed after an operation to remove the spleen.

Waiting for test results

Waiting for test results can be a difficult time. It may take up to 2 weeks for the results to be ready.

You may find it helpful to talk to family members or a close friend. Your specialist nurse can also provide support.

You can talk to one of our cancer support specialists for free on 0808 808 0000, 7 days a week, 8am to 8pm.

Booklets and resources

Staging and grading of SMZL

Your test results give your cancer team more information about the lymphoma. This includes:

  • The stage

    Staging describes how many areas of the body are affected by lymphoma and where these areas are.

  • The grade

    Grading describes how and how quickly the lymphoma cells are likely to grow. SMZL is a low grade lymphoma. This means it usually develops slowly. Rarely, it can change (transform) into high grade lymphoma. High grade lymphoma grows more quickly and needs treatment straight away.

Knowing the stage and grade of the lymphoma helps your cancer team plan the right treatment for you.

We have more information about staging and grading non-Hodgkin lymphoma.

Treatment for SMZL

A team of specialists will meet to discuss the best possible treatment for you. They are called a multidisciplinary team (MDT).

After the MDT meeting, you will usually meet with your cancer doctor and specialist nurse. They will explain the different treatments and their side effects. They will also talk to you about things to consider when making treatment decisions.

Your treatment options will depend on:

  • the stage of the lymphoma
  • your general health
  • your preferences.

If tests show that you have hepatitis C (HCV), you will have antiviral drugs to treat this infection. But SMZL usually develops slowly.

If you have no symptoms, you may not need any treatment. Instead, you may have regular tests and appointments to monitor the lymphoma and check for signs that you need to start treatment. This is called watch and wait. It may also be called active surveillance or active monitoring. It is a way of safely delaying treatment until you need it.

If you need to start treatment, it may include one of the following. You may have some treatments as part of a clinical trial. 

  • Cancer drug treatments

    SMZL is usually treated with either:

    Sometimes other combinations may be used, such as R-CVP.

  • Surgery to remove the spleen (splenectomy)

    Surgery to remove the spleen may sometimes be useful for this type of lymphoma. If the spleen is not too large, this operation can be done using laparoscopic surgery. This is sometimes called keyhole surgery.

  • Radiotherapy

    Radiotherapy uses high-energy rays called radiation to treat cancer. It destroys cancer cells in the area you have it.

    You may have low doses of radiotherapy to the spleen. This treatment may be used if the enlarged spleen is causing symptoms, but you are not well enough to have surgery or chemotherapy. 

Treating SMZL relapse

Treatment for SMZL is often very effective. It may make all signs of lymphoma disappear for a time. Some people will not need further treatment for many years. But SMZL often comes back. This is called recurrence or relapse.

Your treatment may depend on the treatment you have had and how long your remission lasted.

If you have a relapse with no symptoms, you may have ongoing monitoring with tests and scans. If you need to start treatment, this may involve the following:

  • radiotherapy to treat an area of lymphoma that is causing symptoms
  • rituximab
  • rituximab with chemotherapy
  • surgery to remove the spleen
  • intensive treatment with a stem cell transplant
  • targeted therapy drugs, such as zanubrutinib.

Your cancer team will talk to you about the best options for your situation.

Treating transformed SMZL

Sometimes SMZL can change from low grade into high grade lymphoma. This is called transformation or transformed SMZL. It is not common. But your cancer team will do tests to check for this when you are diagnosed or have a relapse of SMZL.

High grade lymphoma grows more quickly and is treated differently. Transformed SMZL is treated in the same way as another type of lymphoma called DLBCL.

After SMZL treatment

Follow-up after treatment for SMZL

You will have regular check-ups during and after your SMZL treatment. Your cancer doctor or specialist nurse will explain what to expect.

Follow-up appointments are a good time for you to talk to your cancer doctor or specialist nurse about any concerns you have. Tell them as soon as possible if you have any problems or notice new symptoms between appointments. We have more information about follow-up care after treatment.

Sometimes side effects may continue or develop months or years after treatment. These are called late effects. We have more information about late effects of lymphoma treatment.

Wellbeing and recovery

Looking after yourself can help speed up your recovery after SMZL treatment. Even small lifestyle changes may improve your wellbeing and help you feel as well as possible during and after treatment.

Even if you already have a healthy lifestyle, you may choose to make some positive changes after treatment. We have more information on leading a healthy lifestyle after treatment.

Support for someone with SMZL

People often have many different feelings during and after SMZL treatment. If you have finished treatment, you may feel relieved it has ended, but worried about what might happen in the future.

It is important to know where to get support or information if you need it. People often need support even some time after SMZL treatment. But sometimes it is difficult to know who to ask for help.

You can:

You may also find the HOPE programme helpful. The programme is a free 6 week self-management course designed to help you develop techniques and strategies when living with or after cancer. Topics include goal setting, fatigue management, and wellbeing.

You can sign up for the online HOPE programme. Or to find out more about face to face programmes in your area, email ServiceOpsSupport@macmillan.org.uk

Other organisations who offer information and support

  • Blood Cancer UK offers support and information to people affected by blood cancers, including lymphoma.
  • Lymphoma Action provides high quality information and support for people affected by lymphoma. It provides helpline services and a range of peer support including online support meetings, educational events and webinars. Its website includes TrialsLink, a database of lymphoma clinical trials.

More information and advice

We know cancer can affect you physically, emotionally and financially. We have information and advice about different ways cancer might impact you, such as help with:

About our information

This information has been written, revised and edited by Macmillan Cancer Support’s Cancer Information Development team. It has been reviewed by expert medical and health professionals and people living with cancer.

  • References

    Below is a sample of the sources used in our lymphoma information. If you would like more information about the sources we use, please contact us at informationproductionteam@macmillan.org.uk

     

    Cwynarski K, Marzolini MAV, Barrington SF, et al. The management of primary mediastinal B-cell lymphoma: a British Society for Haematology Good Practice Paper. Br J Haematol. 2019;185:402-9.

     

    Eyre TA, Bishton MJ, McCulloch R, et al. Diagnosis and management of mantle cell lymphoma: A British Society for Haematology Guideline. Br J Haematol. 2024;204(1):108–26.

     

    Ferreri AJM, Illerhaus G, Doorduijn K, et al., on behalf of the EHA and ESMO Guidelines Committees. Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35(6):491-507.

     

    Fox CP, Ahearne MJ, Pettengell R, et al. Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline. Br J Haematol. 2022;196:507-22.

     

    Fox CP, Chaganti S, McIlroy G, et al. The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology Guideline. Br J Haematol. 2024;204(4):1178–92.

     

    McNamara C, Montoto S, Eyre TA, et al. The investigation and management of follicular lymphoma. Br J Haematol. 2020;191:363-81.

     

    Pratt G, El-Sharkawi D, Kothari J, et al. Diagnosis and management of Waldenström macroglobulinaemia—A British Society for Haematology guideline. Br J Haematol. 2022;197:171–87.

     

    Walewska R, Eyre TA, Barrington S, et al. Guideline for the diagnosis and management of marginal zone lymphomas: A British Society of Haematology Guideline. Br J Haematol. 2024;204(1):86–107.

Date reviewed

Reviewed: 01 November 2024
|
Next review: 01 November 2027
Trusted Information Creator - Patient Information Forum
Trusted Information Creator - Patient Information Forum

Our cancer information meets the PIF TICK quality mark.

This means it is easy to use, up-to-date and based on the latest evidence. Learn more about how we produce our information.

The language we use


We want everyone affected by cancer to feel our information is written for them.


We want our information to be as clear as possible. To do this, we try to:

  • use plain English
  • explain medical words
  • use short sentences
  • use illustrations to explain text
  • structure the information clearly
  • make sure important points are clear.

We use gender-inclusive language and talk to our readers as ‘you’ so that everyone feels included. Where clinically necessary we use the terms ‘men’ and ‘women’ or ‘male’ and ‘female’. For example, we do so when talking about parts of the body or mentioning statistics or research about who is affected.


You can read more about how we produce our information here.